| Phase 12 trials |
|
Phase 1
|
NCT04187443 |
Jun 2020 → Oct 2026 expected |
diabetic macular edema, macular retinal edema |
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02406989 |
Apr → Aug 2015 |
— |
MingSight Pharmaceuticals Pty Limited |
Completed
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT06979076 |
Jul 2026 → Sep 2028 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
MingSight Pharmaceuticals, Inc |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05720052 |
Feb → Nov 2023 |
chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 |
MingSight Pharmaceuticals, Inc |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT05272813 |
Apr 2022 → Nov 2023 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT03492125 |
May 2018 → Nov 2023 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
MingSight Pharmaceuticals, Inc |
Terminated
|
No outcome recorded
|